Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care. Kim K, Ye BD. Inflamm Bowel Dis 2025 Nov 4:izaf243. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim K, Ye BD. Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care. Inflamm Bowel Dis 2025 Nov 4:izaf243. doi: 10.1093.
PMID: 41189090